Swedish medical technology company Getinge delivered second-quarter results that topped analyst expectations, driven in part by a 336 million Swedish crown tariff refund that padded its bottom line. The company, which makes equipment for surgery, intensive care, and sterilization, reported adjusted earnings before interest, taxes, and amortization (EBITA) of 1.48 billion crowns, ahead of the 1.37 billion-crown consensus estimate cited by Reuters.
The adjusted EBITA margin reached 17.6%, a figure that included the tariff refund as a meaningful contributor, alongside price increases and productivity improvements. Getinge flagged that US import tariffs had been pushing up its costs, forcing it to rethink sourcing and pass some of that burden along to customers. The refund, which the company received during the quarter, helped offset some of those pressures.
What's Behind the Refund?
Getinge, like many global manufacturers, has been grappling with the impact of US tariffs on imported goods. The company had been paying higher duties on certain products, which squeezed margins. The 336 million-crown refund likely stems from a successful appeal or adjustment in tariff classifications, though the company did not provide specific details. Such refunds are not uncommon when companies challenge tariff assessments or when trade policies shift, but they are typically one-off events.
The company also noted minor shipping delays tied to disruptions in the Middle East, but said it has largely offset higher freight costs through alternative routes. Getinge kept its 2026 organic sales growth outlook of 3%-5%, signaling confidence in its underlying business despite the headwinds.
What It Means for Investors
For investors, the key question is how much of this quarter's margin improvement is sustainable. The 336 million-crown refund represents about 23% of adjusted EBITA, meaning a big slice of the 17.6% margin likely won't repeat. Analysts and investors typically “normalize” results by stripping out one-off items to gauge the underlying earnings power of a business.
The more durable signals are whether Getinge can keep expanding profitability through repeatable levers like pricing discipline, manufacturing efficiency, and supply-chain changes once that accounting tailwind disappears. The company's ability to pass on higher costs to customers and improve productivity will be critical in the coming quarters.
Getinge's performance comes amid a broader backdrop of medtech companies navigating tariff uncertainty and supply chain disruptions. For context, Intuitive Surgical also beat Q2 estimates but saw its stock fall on a steady 2026 outlook, highlighting how investors are scrutinizing forward guidance. Similarly, RBC sees J&J's drug pipeline driving growth through 2027, with a medtech rebound ahead, suggesting the sector is under pressure to show consistent improvement.
Broader Market Context
Getinge's results also reflect the challenges facing European exporters in a trade environment shaped by US tariffs. The company's experience mirrors that of other industrial firms that have had to adjust sourcing and pricing strategies. For instance, Assa Abloy beat Q2 estimates despite currency headwinds, showing that Swedish companies can still deliver growth even with external pressures.
Meanwhile, Yara's profit rose but missed estimates as gas costs and cautious buyers weighed, underscoring the uneven recovery across industries. For Getinge, the tariff refund provided a temporary boost, but the company's long-term margin trajectory will depend on its ability to navigate trade policy shifts and maintain pricing power.
Looking Ahead
Getinge's 2026 organic sales growth target of 3%-5% remains intact, suggesting management sees a path to steady expansion. However, investors will be watching for signs that the company can sustain margin improvement without relying on one-off gains. The next few quarters will reveal whether the pricing and productivity measures are enough to offset tariff costs and other headwinds.
For everyday investors, the lesson is to look beyond headline beats and understand what drove them. A refund can make a quarter look cleaner than the underlying business, so it's important to focus on the repeatable drivers of profitability. Getinge's story is a reminder that in a world of trade disruptions and supply chain shifts, companies that can adapt their sourcing and pricing strategies are better positioned for the long haul.
